TUL ranked among the top 101 in the 2026 Pharmaceutical Industry, top 15 in API business, and top 20 in New Drug BD strength

UBT251 injection has been successfully included in the key variety list of the Greater Bay Area Center for Drug Evaluation and Inspection by the National Medical Products Administration

At Seoul CPHI, TUL deepens cooperation in the Korean market

The United Laboratories Animal Healthcare Co., Ltd. showcased at SIAVS Brazil Livestock Expo, delving deeper into overseas markets in Latin America

TUL ranks 30th in the "Top 100 Enterprises in China's Pharmaceutical Industry by Main Business Revenue in 2025"

Further expanding into the West African livestock market, The United Laboratories Animal Healthcare Co., Ltd. showcased at the 2026 AVIANA West Africa International Agricultural and Livestock Expo in Nigeria

UBT251 INJECTION COMPLETED FIRST PARTICIPANT DOSING IN PHASE III CLINICAL STUDY FOR OVERWEIGHT OR OBESITY IN CHINA

Significant Progress in Innovative Drug R&D and Continued Globalization Efforts Profit Attributable to Owners of the Company Reached Approximately RMB347.6 Million

FDA APPROVAL OF IND FOR THE GROUP’S PRODUCT UBT48128 TABLETS